Bolt Biotherapeutics
BOLT
56 hedge funds and large institutions have $38.5M invested in Bolt Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 3.58% → 3.56% (-0.02%)
8% less funds holding
Funds holding: 61 → 56 (-5)
30% less capital invested
Capital invested by funds: $54.8M → $38.5M (-$16.3M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$1.6M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$914K |
| 3 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$357K |
| 4 |
CCM
CAAS Capital Management
New York
|
+$242K |
| 5 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$241K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.66M |
| 2 |
Morgan Stanley
New York
|
-$703K |
| 3 |
NM
Newtyn Management
New York
|
-$307K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$306K |
| 5 |
Renaissance Technologies
New York
|
-$299K |
BOLT Hedge Fund Activity: Q3 2022 in Review
56 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2022, worth a combined $38.5M — down 30% from $54.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BOLT and 8 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $1.6M. The largest seller was Novo Holdings A/S, cutting an estimated $1.66M.
- 56 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2022, down from 61 in Q2 2022.
- Funds reported $38.5M of Bolt Biotherapeutics stock for Q3 2022, down 30% quarter-over-quarter.
- 8 funds opened new Bolt Biotherapeutics positions in Q3 2022 and 13 closed out, a net change of -5 holders.
- The largest Bolt Biotherapeutics buyer in Q3 2022 was OrbiMed, an estimated $1.6M added.
- The largest Bolt Biotherapeutics seller in Q3 2022 was Novo Holdings A/S, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2022.